INTRODUCTION
As many as 170,000 patients with solid tumors develop brain metastases in the US each year (1) . In the absence of effective treatment options, the prognosis for patients with brain metastases is poor, with an estimated median survival less than 4 months (1). Many studies exclude patients with brain metastases, despite the urgent need to develop treatments for this critical problem.
Treatment of brain metastases sometimes includes steroids to control edema, anticonvulsants to control seizures, resection when appropriate, whole brain irradiation, radiosurgery and/or chemotherapy with efficacy limited by the difficulty posed by the bloodbrain barrier (2) (3) (4) (5) .
GRN1005 (formerly known as ANG1005) is a conjugate of Angiopep-2 (peptide backbone) and three molecules of paclitaxel which contribute approximately 50% of its molecular weight (6) . While standard paclitaxel is marketed in a formulation that contains Cremophor EL, GRN1005 is Cremophor-free (7). This is advantageous, as many toxicities, such as hypersensitivity reactions, have been attributed to the Cremophor EL associated with paclitaxel (8).
GRN1005 can actively penetrate into the brain compartment by targeting low-density lipoprotein receptor-related protein-1 (LRP-1), which is highly expressed on the surface of the blood-brain barrier. In vivo and in vitro data show that the brain's uptake rate of 6 lysosomal compartments, releasing free paclitaxel to exert its antimitotic functions at the site of disease. Paclitaxel does not reach high concentrations in brain tumor tissue following normal IV injection, potentially due to transport by p-glycoprotein (10, 11) . The potential for GRN1005 to cross the blood-brain barrier and specifically target tumor cells in patients with brain metastases would offer significant therapeutic advantages over currently available treatments.
Herein we report the results of a first-in-human, open-label, phase I clinical study conducted to assess the safety, tolerability, pharmacokinetics (PK) and preliminary evidence of efficacy of GRN1005 in adult patients with advanced solid tumors. 
PATIENTS AND METHODS

Eligibility Criteria
To be eligible, patients had to be ≥ 18 years of age and have progressing and measurable metastatic or advanced solid tumor not amenable to established forms of therapy, an Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and adequate hematologic, hepatic and renal function; patients enrolled into the expanded maximum tolerated dose (MTD) cohort were required to show evidence of progressing brain metastases by computed tomography (CT) or magnetic resonance imaging (MRI) scan prior to study entry. Patients with symptomatic brain metastases were not excluded from the study. Patients with unstable or uncompensated organ system dysfunction, known severe hypersensitivity to paclitaxel, severe toxicity with previous taxane treatment and/or persistent ≥ Grade 2 neurotoxicity were excluded. Treatment with P450 CYP 3A4 and 2C8 enzyme-inducing anticonvulsant drugs during the study and within 14 days of day 1, and chemotherapy, immunotherapy, radiotherapy and investigational agents during the study and within 4 weeks of day 1 were prohibited. Institutional Review Board (IRB) approval and written informed consents were obtained before study-related procedures were started.
Study Design
This first-in-human, phase I, open-label study used a rapid dose-escalation design. (12) The starting dose, 30 mg/m 2 , was calculated based on toxicology studies in rats and dogs. Escalation by dose-doubling was performed for two dose levels (60 and 120 mg/m 2 ), after which a modified Fibonacci escalation scheme (i.e., increases of 67%, 50%, 40% and 33%) was used to guide dose increases. GRN1005 was administered by intravenous (IV) infusion at a concentration of 1.5 mg/mL and a rate of 8.0-8.5 mL/minute (~1 hour) once every 21 days. Premedication was not allowed during Cycle 1 and was allowed only as medically indicated thereafter.
In the dose-escalation phase, patients were enrolled sequentially into cohorts of 1-3 patients each, until a ≥ Grade 2 drug-related toxicity was observed, at which point that and subsequent cohorts were expanded to a minimum of three patients. If one patient experienced a dose-limiting toxicity (DLT), a minimum of six patients were enrolled at that dose. Dose escalation continued until > 1 of 6 patients in a cohort experienced a DLT during Cycle 1, after which a lower dose was explored. Once identified, the MTD cohort was expanded to obtain additional safety and PK data and to explore potential antitumor activity in patients with brain metastases. Patients remained on study until disease progression, death, unacceptable toxicity or consent withdrawal.
Dose-Limiting Toxicity and Maximum Tolerated Dose
DLT was defined as any of the following occurring during Cycle 1 that were treatment-emergent and possibly related to GRN1005: any Grade 3 or 4 nonhematologic toxicity; febrile neutropenia; Grade 4 neutropenia lasting ≥ 7 days; Grade 4 thrombocytopenia; Grade 2 peripheral neuropathy lasting ≥ 7 days or ≥ Grade 3 peripheral neuropathy of any duration. The MTD was defined as the dose level at which ≤ 1 of 6 patients in a cohort developed a DLT during Cycle 1. Dose reductions (one dose level)
were permitted for patients who experienced a DLT, and patients were allowed two dose reductions.
Evaluation of Safety
Adverse events (AEs) were recorded for patients who received at least one dose of GRN1005. Severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0.
Vital signs were measured at various timepoints up to 4 hours after infusion and regularly between infusions. Electrocardiograms were obtained prior to infusion and 30 minutes and 3 hours after infusion during Cycle 1. Hematology, blood chemistry and urine values were monitored regularly, and physical and neurologic examinations were also performed.
Neurocognitive testing
Neurocognitive testing was done at baseline and every six weeks during treatment to assess potential neurotoxic effects. The battery included the following tests: Hopkins Verbal Learning Tests -Revised (HVLT-R); Trail Making; Controlled Oral Word Association (COWA); and Grooved Pegboard (13, 14) . Test results were sent for central evaluation and reading by an independent reviewer.
Immunogenicity
Serum for assessment of anti-GRN1005 antibodies was collected pre-dose at each treatment cycle and at the final visit. Anti-GRN1005 antibodies were assayed using a validated enzyme-linked immunosorbent assay (ELISA) with a sensitivity ≤ 0.56 μg/mL (15, 16 
Pharmacokinetics (PK)
Plasma samples for PK characterization were collected prior to infusion, at end of infusion and 30 minutes, 1, 2, 3, 4 and 24 hours after infusion during Cycles 1 and 3.
GRN1005 and paclitaxel concentrations were determined using validated liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) methods (17, 18).
Concentrations of ANG1005 in human ethylenediaminetetraacetic acid (EDTA) K 2 plasma were determined using Liquid Chromatography/Mass Spectrometry/ Mass Spectrometry (LC/MS/MS) with a limit of quantitation of 0.50 -2.00 µg/mL (17, 18).
GRN1005 (MW of 5109.14 daltons) was extracted by protein precipitation and quantified by peak area ratio. A weighed 1/X 2 linear regression was performed to determine the concentration of GRN1005.
Concentration of free paclitaxel was determined using LC/MS/MS with a limit of quantitation of 100 ng/mL. Paclitaxel (MW of 853.9 daltons) was extracted from an aliquot of human EDTA plasma containing GRN1005 using an automated liquid-liquid extraction, then injected into a liquid chromatograph equipped with a tandem mass spectrometry detector and quantified by peak area ratio. A weighed 1/X 2 linear regression was performed to determine the concentration of paclitaxel.
Evaluation of Efficacy
Treatment efficacy was evaluated by CT or MRI per Response Evaluation Criteria in
Solid Tumors (RECIST) 1.0(19) in all organs in which disease was present, including brain, before treatment and every six weeks thereafter. Briefly, complete response (CR) was disappearance of all lesions; partial response (PR) was ≥ 30% reduction in the sum of the longest diameters of the lesions; stable disease (SD) was sum of longest diameters not decreased more than 30% and not increased more than 20%; and progressive disease (PD) was ≥ 20% increase in the sum of the longest diameters of the lesions. Overall response was determined by the primary physician; scans from patients dosed > 300 mg/m 2 and who experienced tumor shrinkage per RECIST were later sent to an independent radiologist for examination of lesion response per organ system.
Statistical Analysis
Descriptive statistics are provided for demographic, safety, PK and efficacy data.
Categorical data are summarized by frequency and percentages; continuous data are summarized by mean and standard deviation (SD) or median and range, as appropriate.
Changes from baseline in neurocognitive test results were assessed using paired t-tests. 
RESULTS
Patient Characteristics
Fifty-six patients were enrolled across three study centers in the US ( Demographics and clinical characteristics at study entry are summarized in Table 1 .
Forty-one patients (73%) had brain metastases at the time of enrollment, including both patients who had and had not received prior brain radiation and patients treated with steroids, including while receiving GRN1005. The median number of prior therapies was 4 (range: 0-22).
Reasons for study withdrawal were: disease progression (n = 33), AEs (all causalities including not related to drug; n = 12), investigator decision (n = 4), consent withdrawal (n = 6) and death (n = 1).
Dose Escalation
Patients were enrolled sequentially into the following dose cohorts: 30, 60, 120, 200, 300, 420, 500, 550, 650 and 700 mg/m 2 . At the 60 mg/m 2 dose, Grade 2 neutropenia and anemia occurred, and the dose level and subsequent dose-escalation cohorts were expanded to include 3-6 patients. At the 500 mg/m cloudy solutions did not jeopardize patient safety; enrollment was nevertheless temporarily interrupted to investigate the formulation. Analyses determined that at higher concentrations, GRN1005 was precipitating out of solution; this did not affect the purity of GRN1005 but did influence its potency. These patients were still included in safety and efficacy evaluations. A modified dilution process was subsequently implemented and dosing was repeated as of the 300 mg/m 2 dose level in the interest of rigor. These findings were reported to the Institutional Review Boards and FDA.
Dose-Limiting Toxicities and Maximum Tolerated Dose
No DLTs were reported at doses ≤ 550 mg/m , five patients experienced DLTs in the first cycle: febrile neutropenia (n = 2), dehydration with stomatitis (n = 1), neuropathy (n = 1) and pneumonia (n = 1).
Safety
All 56 patients received at least one dose of GRN1005 and were evaluated for safety and tolerability. Dose reductions were required in 11 patients (20%). Myelosuppression was the major toxicity ( Table 2) 
Neurocognitive testing
Twenty patients performed at least one post-treatment neurocognitive test battery and were included in the analysis. Results revealed no evidence that GRN1005 causes CNS toxicity. One patient who experienced SD for > 7.5 months showed significant improvement in memory, processing speed and executive function after 6, 12, 18 and 24 weeks of therapy. Radiographic images of the patient's brain lesion showed changes in tumor size from baseline of -9%, +3%, -6% and -3% at 6, 12, 18 and 24 weeks, respectively.
Pharmacokinetics
Fifty-five patients had at least one post-treatment PK sample drawn and were included in the analysis. The PK of GRN1005 appeared to be dose proportional. After single dose IV infusion, GRN1005 showed an overall mean time to maximum observed plasma concentration (T max ) ranging from 0 to 0.5 hours after infusion (Table 3 
μM for paclitaxel and Cmax = 1187 μM for GRN1005 versus 13 μM for paclitaxel). There was no evidence of accumulation of unconjugated paclitaxel based on PK analyses for Cycle 1 versus Cycle 3.
Efficacy
All 56 patients were included in the efficacy evaluation. Response data were available for 43 patients as follows: 39 patients had at least one post-treatment evaluation and four patients came off study early for clinical progression. The remaining 13 patients were not re-evaluated post-treatment for the following reasons: consent withdrawal (n = 5), AEs (n = 4), investigator decision (n = 3) and death (n=1); these patients were considered treatment failures.
Best overall responses (n = 43) are shown in Figure 2A and Table 4 . Five patients (9%) achieved a PR (breast cancer, n = 2; non-small cell lung cancer (NSCLC), n = 2, 1 unconfirmed; ovarian cancer, n = 1). All PR's were observed at the 650 mg/m 2 dose (MTD; Table 4 ). Among the five patients achieving PR, all also experienced shrinkages in their brain lesions (Figure 2B, 2C) as assessed by an independent radiologist; brain responses ranged from -17% to -50%. Furthermore, three of these patients had failed prior taxane therapy. No patients in Figure 2B The most frequently observed toxicity was myelosuppression, which was generally manageable and reversible with standard treatments. Adverse events such as peripheral neuropathy, infusion reactions and rashes were seen in a minority of patients, and no CNS toxicity was revealed by neurocognitive testing and neurologic examination. Reversal of neurological deficits after treatment with GRN1005 was observed in one patient who showed marked improvements in memory, processing speed and executive function after only 6 weeks of therapy; these improvements were accompanied by a 9% shrinkage of brain metastases.
The PK of GRN1005 showed dose proportional increases in C max and AUC inf at doses ranging from 30 to 700 mg/m 2 . The mean t 1/2 was 3.6 hours; in contrast, the t 1/2 for nab-paclitaxel is 21.6 hours and 20. 
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achieve an overall PR had a PR in her brain lesions. This data points to a possible distinct ability of GRN1005 to effectively treat patients with brain metastases as well as active systemic disease.
In summary, GRN1005 is a new chemical entity with a unique targeting mechanism.
It was well tolerated and showed evidence of activity in patients with advanced solid tumors and brain metastases. These results suggest that GRN1005 is able to penetrate the blood- 
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